azaperone has been researched along with Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bruns, A; Buss, P; Koeppel, K; Meyer, LC; Stemmet, GP; Zeiler, GE; Zimmerman, D | 1 |
| da Silva, AA; Dubinion, JH; Hall, JE | 1 |
1 trial(s) available for azaperone and Hypertension
| Article | Year |
|---|---|
Compared to etorphine-azaperone, the ketamine-butorphanol-medetomidine combination is also effective at immobilizing zebra (Equus zebra).
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Animals; Animals, Wild; Azaperone; Blood Pressure; Butorphanol; Cross-Over Studies; Drug Combinations; Equidae; Etorphine; Female; Hypertension; Hypnotics and Sedatives; Hypoxia; Immobilization; Ketamine; Male; Medetomidine; Oxygen; Random Allocation | 2019 |
1 other study(ies) available for azaperone and Hypertension
| Article | Year |
|---|---|
Enhanced blood pressure and appetite responses to chronic central melanocortin-3/4 receptor blockade in dietary-induced obesity.
Topics: Animals; Appetite; Azaperone; Blood Pressure; Dietary Fats; Energy Intake; Heart Rate; Hypertension; Melanocyte-Stimulating Hormones; Obesity; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, Melanocortin, Type 3; Receptor, Melanocortin, Type 4; Weight Gain | 2010 |